LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 4 von insgesamt 4

Suchoptionen

  1. Artikel: The synthesis of anticancer sulfonated indolo[2,1-a]isoquinoline and benzimidazo[2,1-a]isoquinolin-6(5H)-ones derivatives via a free radical cascade pathway

    Pan, You-lu / Gong, Xiao-meng / Hao, Rong-rong / Zeng, Shen-xin / Shen, Zheng-rong / Huang, Wen-hai

    RSC advances. 2022 Mar. 29, v. 12, no. 16

    2022  

    Abstract: A facile CuBr₂ induced radical relay addition/cyclization of activated alkenes with substituted-thiosulfonates has been achieved, leading to a broad range of sulfonated indolo[2,1-a]isoquinolines and benzimidazo[2,1-a]isoquinolin-6(5H)-ones in moderate ... ...

    Abstract A facile CuBr₂ induced radical relay addition/cyclization of activated alkenes with substituted-thiosulfonates has been achieved, leading to a broad range of sulfonated indolo[2,1-a]isoquinolines and benzimidazo[2,1-a]isoquinolin-6(5H)-ones in moderate to good yields. In particular, some compounds exhibit bioactivity against cancer cell lines. This protocol shows advantages of low-cost, base-free, simple operation, and broad functional group tolerance.
    Schlagwörter alkenes ; bioactive properties ; free radicals ; isoquinolines ; neoplasm cells
    Sprache Englisch
    Erscheinungsverlauf 2022-0329
    Umfang p. 9763-9772.
    Erscheinungsort The Royal Society of Chemistry
    Dokumenttyp Artikel
    ISSN 2046-2069
    DOI 10.1039/d1ra06981k
    Datenquelle NAL Katalog (AGRICOLA)

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: The synthesis of anticancer sulfonated indolo[2,1-

    Pan, You-Lu / Gong, Xiao-Meng / Hao, Rong-Rong / Zeng, Shen-Xin / Shen, Zheng-Rong / Huang, Wen-Hai

    RSC advances

    2022  Band 12, Heft 16, Seite(n) 9763–9772

    Abstract: ... A facile ... ...

    Abstract A facile CuBr
    Sprache Englisch
    Erscheinungsdatum 2022-03-29
    Erscheinungsland England
    Dokumenttyp Journal Article
    ISSN 2046-2069
    ISSN (online) 2046-2069
    DOI 10.1039/d1ra06981k
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: The copper-catalyzed oxidation of arylmethyl triazines with H

    Zeng, Ming / Yuan, Zi-Xin / Wen, Lin-Fei / Jiang, Dengzhao / Lu, Hui / Liu, Wenbo / Dai, Jun / Zeng, Shen-Xin

    Organic & biomolecular chemistry

    2022  Band 20, Heft 27, Seite(n) 5406–5411

    Abstract: We report an efficient copper-catalyzed dehydrogenation method for the synthesis of aroyl triazines from arylmethyl triazines with water in the absence of additional oxidants or hydrogen acceptors. The use of substrates with both electron-donating and ... ...

    Abstract We report an efficient copper-catalyzed dehydrogenation method for the synthesis of aroyl triazines from arylmethyl triazines with water in the absence of additional oxidants or hydrogen acceptors. The use of substrates with both electron-donating and electron-withdrawing groups resulted in moderate to good yields. Using liquid chromatography-mass spectrometry,
    Mesh-Begriff(e) Catalysis ; Copper/chemistry ; Hydrogen ; Oxidants/chemistry ; Triazines/chemistry ; Water
    Chemische Substanzen Oxidants ; Triazines ; Water (059QF0KO0R) ; Copper (789U1901C5) ; Hydrogen (7YNJ3PO35Z)
    Sprache Englisch
    Erscheinungsdatum 2022-07-13
    Erscheinungsland England
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2097583-1
    ISSN 1477-0539 ; 1477-0520
    ISSN (online) 1477-0539
    ISSN 1477-0520
    DOI 10.1039/d2ob00582d
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.

    Pan, You-Lu / Zeng, Shen-Xin / Hao, Rong-Rong / Liang, Mei-Hao / Shen, Zheng-Rong / Huang, Wen-Hai

    European journal of medicinal chemistry

    2022  Band 238, Seite(n) 114442

    Abstract: Chronic myeloid leukemia (CML) is a malignant disease of the hematopoietic system with crucial pathogenic protein named BCR-ABL, which endangers the life of patients severely. As a milestone of targeted drug, Imatinib has achieved great success in the ... ...

    Abstract Chronic myeloid leukemia (CML) is a malignant disease of the hematopoietic system with crucial pathogenic protein named BCR-ABL, which endangers the life of patients severely. As a milestone of targeted drug, Imatinib has achieved great success in the treatment of CML. Nevertheless, inevitable drug resistance of Imatinib has occurred frequently in clinical due to the several mutations in the BCR-ABL kinase. Subsequently, the second-generation of tyrosine kinase inhibitors (TKIs) against BCR-ABL was developed to address the mutants of Imatinib resistance, except T315I. To date, the third-generation of TKIs targeting T315I has been developed for improving the selectivity and safety. Notably, the first allosteric inhibitor has been in market which could overcome the mutations in ATP binding site effectively. Meanwhile, some advanced technology, such as proteolysis-targeting chimeras (PROTAC) based on different E3 ligand, are highly expected to overcome the drug resistance by selectively degrading the targeted proteins. In this review, we summarized the current research progress of inhibitors and degraders targeting BCR-ABL for the treatment of CML.
    Mesh-Begriff(e) Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Benzamides/therapeutic use ; Drug Resistance, Neoplasm ; Fusion Proteins, bcr-abl ; Humans ; Imatinib Mesylate/therapeutic use ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology ; Piperazines/pharmacology ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Pyrimidines/pharmacology
    Chemische Substanzen Antineoplastic Agents ; Benzamides ; Piperazines ; Protein Kinase Inhibitors ; Pyrimidines ; Imatinib Mesylate (8A1O1M485B) ; Fusion Proteins, bcr-abl (EC 2.7.10.2)
    Sprache Englisch
    Erscheinungsdatum 2022-05-06
    Erscheinungsland France
    Dokumenttyp Journal Article ; Review
    ZDB-ID 188597-2
    ISSN 1768-3254 ; 0009-4374 ; 0223-5234
    ISSN (online) 1768-3254
    ISSN 0009-4374 ; 0223-5234
    DOI 10.1016/j.ejmech.2022.114442
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang